Article History
First Online: 15 September 2020
Declarations
:
: Dr. Correll has been a consultant and/or advisor to or has received honoraria from: Acadia Pharmaceuticals Inc., Alkermes, Allergan, Angelini Pharma, Axsome Therapeutics Inc., Gedeon Richter, Gerson Lehrman Group, Intra-Cellular Therapies Inc., Janssen Pharmaceuticals, Inc./Johnson & Johnson, LB Pharma, Lundbeck, MedAvante-ProPhase Inc., Medscape, Neurocrine Biosciences, Noven Pharmaceuticals Inc., Otsuka Pharmaceutical Co., Pfizer Inc., Recordati, Rovi, Sumitomo Dainippon Pharma, Sunovion Pharmaceuticals Inc., Supernus Pharmaceuticals Inc., Takeda Pharmaceutical Co., and Teva Pharmaceutical Industries Ltd. He has provided expert testimony for Janssen Pharmaceuticals, Inc. and Otsuka Pharmaceutical Co. He served on a Data Safety Monitoring Board for Lundbeck, Rovi, Supernus Pharmaceuticals Inc, and Teva Pharmaceutical Industries Ltd. He received royalties from UpToDate and grant support from Janssen Pharmaceuticals, Inc. and Takeda Pharmaceutical Co. He is also a stock option holder of LB Pharma. Dr Cernea received payment for lectures from AstraZeneca, Boehringer Ingelheim, Berlin-Chemie Menarini, Eli Lilly, MSD, Novo Nordisk, Sanofi, Servier Pharma, for clinical trial Steering Committee meetings as National Lead Investigator for DECLARE-TIMI58 from TIMI Study Group, consultant fees for Advisory Board from AstraZeneca and support for travel to meetings from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Sanofi, MSD, Novo Nordisk, Worwag Pharma. Drs Dima and Manu have nothing to declare.
: The authors received no specific funding for this work.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.